643 related articles for article (PubMed ID: 26910191)
1. Adapting conventional cancer treatment for immunotherapy.
Qiao J; Liu Z; Fu YX
J Mol Med (Berl); 2016 May; 94(5):489-95. PubMed ID: 26910191
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
3. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
Yan Y; Kumar AB; Finnes H; Markovic SN; Park S; Dronca RS; Dong H
Front Immunol; 2018; 9():1739. PubMed ID: 30100909
[TBL] [Abstract][Full Text] [Related]
4. Cancer Immunotherapy in Older Patients.
Marrone KA; Forde PM
Cancer J; 2017; 23(4):219-222. PubMed ID: 28731944
[TBL] [Abstract][Full Text] [Related]
5. Emerging Opportunities and Challenges in Cancer Immunotherapy.
Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
[TBL] [Abstract][Full Text] [Related]
6. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
Patel SA; Minn AJ
Immunity; 2018 Mar; 48(3):417-433. PubMed ID: 29562193
[TBL] [Abstract][Full Text] [Related]
7. Immunological Mechanisms Underneath the Efficacy of Cancer Therapy.
Galluzzi L; Zitvogel L; Kroemer G
Cancer Immunol Res; 2016 Nov; 4(11):895-902. PubMed ID: 27803050
[TBL] [Abstract][Full Text] [Related]
8. The importance for immunoregulation for long-term cancer control.
Fusi A; Dalgleish A
Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
[TBL] [Abstract][Full Text] [Related]
9. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.
Shahabi V; Postow MA; Tuck D; Wolchok JD
Am J Clin Oncol; 2015 Feb; 38(1):90-7. PubMed ID: 25616204
[TBL] [Abstract][Full Text] [Related]
10. Therapy-induced microenvironmental changes in cancer.
Ma Y; Yang H; Pitt JM; Kroemer G; Zitvogel L
J Mol Med (Berl); 2016 May; 94(5):497-508. PubMed ID: 26931513
[TBL] [Abstract][Full Text] [Related]
11. Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment.
Ishihara D; Pop L; Takeshima T; Iyengar P; Hannan R
Cancer Immunol Immunother; 2017 Mar; 66(3):281-298. PubMed ID: 27743027
[TBL] [Abstract][Full Text] [Related]
12. Challenges faced when identifying patients for combination immunotherapy.
Ernstoff MS; Gandhi S; Pandey M; Puzanov I; Grivas P; Montero A; Velcheti V; Turk MJ; Diaz-Montero CM; Lewis LD; Morrison C
Future Oncol; 2017 Aug; 13(18):1607-1618. PubMed ID: 28835114
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
Yu WD; Sun G; Li J; Xu J; Wang X
Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
[TBL] [Abstract][Full Text] [Related]
14. Immune biological rationales for the design of combined radio- and immunotherapies.
Hader M; Frey B; Fietkau R; Hecht M; Gaipl US
Cancer Immunol Immunother; 2020 Feb; 69(2):293-306. PubMed ID: 31953578
[TBL] [Abstract][Full Text] [Related]
15. Optimizing tumor immune response through combination of radiation and immunotherapy.
El Chediak A; Shamseddine A; Bodgi L; Obeid JP; Geara F; Zeidan YH
Med Oncol; 2017 Aug; 34(9):165. PubMed ID: 28828581
[TBL] [Abstract][Full Text] [Related]
16. Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect - a glimpse to the future.
Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2018 Jul; 27(7):569-572. PubMed ID: 29958097
[TBL] [Abstract][Full Text] [Related]
17. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh L; Ladoire S; Coukos G; Ghiringhelli F
Ann Oncol; 2015 Sep; 26(9):1813-1823. PubMed ID: 25922066
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
Esposito A; Criscitiello C; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Kyi C; Postow MA
Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
Pico de Coaña Y; Choudhury A; Kiessling R
Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
